<DOC>
	<DOCNO>NCT01269593</DOCNO>
	<brief_summary>The purpose study see new drug , name PUH71 , accumulate different part body &amp; inside tumor long PUH71 last blood , give study participant tiny amount . The result study help researcher ( 1 ) plan use PUH71 experimental new drug ( much-higher dos ) treatment cancer , clinical trial ; ( 2 ) know whether PUH71 might use drug detect tumor scanner machine .</brief_summary>
	<brief_title>PET Imaging Cancer Patients Using 124I-PUH71 : A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Patients solid malignancy , myeloproliferative neoplasm , myeloma , and/or lymphoma ( histology confirm MSKCC Department Pathology ) Disease measurable evaluable define RECIST ( 1.1 original version ) tumor response criterion MSKCC IRBapproved clinical research protocol . This apply patient myeloproliferative neoplasm . The presence active myeloproliferative neoplasm determine applicable disease specific diagnostic criterion patient assessment patient 's oncologist trial investigator ( eg , manifestation active MPN splenomegaly , abnormal blood count , etc ) . Age 1890 Negative serum pregnancy test female childbearing age ( 1155 year ) and/or lack childbearing potential No breastfeed Previous allergic reaction contrast medium . Hypersensitivity iodide product . Known hyperthyroidism Hepatic : Bilirubin &gt; 1.5 x institutional upper limit normal ( ULN ) AST/ALT &gt; 2.5 x ULN Albumin &lt; 2 g/dl GGT &gt; 2.5 x ULN IF Alkaline phosphatase &gt; 2.5 x ULN . Renal : Creatinine &gt; 1.5 x ULN creatinine clearance &lt; 60 mL/min . Positive serum pregnancy test female Acute major illness ( e.g. , infection , unstable cardiovascular condition , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PET Scan</keyword>
	<keyword>124I-PUH71</keyword>
	<keyword>10-139</keyword>
</DOC>